Figure 6. T-bet^−/− Tconv cells decrease pathology in the GI tract but do not attenuate GvHD.

(A) B6D2 F1 recipient mice were lethally irradiated (950 cGy) on day -1. Following irradiation on day 0 mice were injected intravenously with 4 × 10⁶ WT or T-bet^−/− Tconv cells supplemented with 3 × 10⁶ WT TCD BM. Mice were monitored for survival and scored twice weekly for clinical GvHD. n=14 for T-bet^−/− recipients, n=11 for WT recipients, n=4 bone marrow only. All recipient mice receiving BM only cells survived until the completion of the experiment. (B) On day 15 post transplantation organs were harvested from WT and T-bet^−/− recipients and evaluated for pathology as described above. Error bars indicate SEM. Statistical significance was determined using Mann-Whitney test. *p<0.05, # p=0.09. Data are combined from 2 individual experiments.